Skip to main content
Top
Published in:

Open Access 16-01-2024 | Graft-Versus-Host Disease | Original Article

The indirect effects of CMV reactivation on patients following allogeneic hematopoietic stem cell transplantation: an evidence mapping

Authors: Xiaojin Wu, Xiao Ma, Tiemei Song, Jie Liu, Yi Sun, Depei Wu

Published in: Annals of Hematology | Issue 3/2024

Login to get access

Abstract

Cytomegalovirus (CMV) reactivation following allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a challenging problem, and the impact on the risk of overall mortality (OM) and non-relapse mortality (NRM) in patients following allo-HSCT is still controversial. Utilizing the evidence mapping method, we aimed to assess the effect of CMV infection on outcomes of patients post-transplantation and identify research gaps through systematic reviews (SRs) and clinical studies. PubMed, EMBASE, Web of Science, and Cochrane library databases were searched from inception until 5 July 2022 to identify relevant literature. After systematic literature screening and data extraction, evidence mapping of the effects of CMV reactivation on patients post-allo-HSCT was conducted. Three SRs and 22 clinical studies were included. In one SR, CMV reactivation was associated with an increased risk of mortality (HR 1.46; 95% CI, 1.24–1.72; P ≤ 0.001). In two SRs, CMV reactivation was associated with NRM. One SR reported CMV reactivation was potentially associated with significant protection against relapse in patients with acute myelocytic leukemia (AML), but no significant correlation with graft-versus-host disease (GVHD) was found. Lastly, in one SR CMV reactivation significantly increased the risk of invasive fungal disease (IFD). Most clinical articles reported that CMV reactivation increased the risk of renal dysfunction, poor graft function, re-hospitalization, and bacterial infections. CMV reactivation following allo-HSCT is associated with an increased risk of OM, NRM, IFD, and renal dysfunction, as well as a reduced risk of relapse in patients with AML.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ljungman P et al (2019) Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis 19(8):e260–e272PubMedCrossRef Ljungman P et al (2019) Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis 19(8):e260–e272PubMedCrossRef
2.
go back to reference Green ML et al (2016) Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol 3(3):e119–e127PubMedPubMedCentralCrossRef Green ML et al (2016) Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol 3(3):e119–e127PubMedPubMedCentralCrossRef
3.
go back to reference Teira P et al (2016) Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood 127(20):2427–2438PubMedPubMedCentralCrossRef Teira P et al (2016) Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood 127(20):2427–2438PubMedPubMedCentralCrossRef
4.
go back to reference Liu YC et al (2012) Cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation: experience in a center with a high seroprevalence of both CMV and hepatitis B virus. Ann Hematol 91(4):587–595PubMedCrossRef Liu YC et al (2012) Cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation: experience in a center with a high seroprevalence of both CMV and hepatitis B virus. Ann Hematol 91(4):587–595PubMedCrossRef
5.
go back to reference Yong MK, Slavin MA, Kontoyiannis DP (2018) Invasive fungal disease and cytomegalovirus infection: is there an association? Curr Opin Infect Dis 31(6):481–489PubMedCrossRef Yong MK, Slavin MA, Kontoyiannis DP (2018) Invasive fungal disease and cytomegalovirus infection: is there an association? Curr Opin Infect Dis 31(6):481–489PubMedCrossRef
6.
go back to reference Manjappa S et al (2014) Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen. Biol Blood Marrow Transplant 20(1):46–52PubMedCrossRef Manjappa S et al (2014) Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen. Biol Blood Marrow Transplant 20(1):46–52PubMedCrossRef
7.
go back to reference Nakamura R et al (2004) Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure. Biol Blood Marrow Transplant 10(1):49–57PubMedCrossRef Nakamura R et al (2004) Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure. Biol Blood Marrow Transplant 10(1):49–57PubMedCrossRef
8.
go back to reference Elmaagacli AH et al (2011) Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood 118(5):1402–1412PubMedCrossRef Elmaagacli AH et al (2011) Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood 118(5):1402–1412PubMedCrossRef
9.
go back to reference Jerry Teng CL et al (2021) Cytomegalovirus management after allogeneic hematopoietic stem cell transplantation: a mini-review. J Microbiol Immunol Infect 54(3):341–348PubMedCrossRef Jerry Teng CL et al (2021) Cytomegalovirus management after allogeneic hematopoietic stem cell transplantation: a mini-review. J Microbiol Immunol Infect 54(3):341–348PubMedCrossRef
10.
go back to reference Jang JE et al (2015) Early CMV replication and subsequent chronic GVHD have a significant anti-leukemic effect after allogeneic HSCT in acute myeloid leukemia. Ann Hematol 94(2):275–282PubMedCrossRef Jang JE et al (2015) Early CMV replication and subsequent chronic GVHD have a significant anti-leukemic effect after allogeneic HSCT in acute myeloid leukemia. Ann Hematol 94(2):275–282PubMedCrossRef
11.
12.
go back to reference Zhang YL et al (2019) Cytomegalovirus infection is associated with AML relapse after allo-HSCT: a meta-analysis of observational studies. Ann Hematol 98(4):1009–1020PubMedCrossRef Zhang YL et al (2019) Cytomegalovirus infection is associated with AML relapse after allo-HSCT: a meta-analysis of observational studies. Ann Hematol 98(4):1009–1020PubMedCrossRef
13.
go back to reference Gimenez E et al (2019) Cytomegalovirus (CMV) infection and risk of mortality in allogeneic hematopoietic stem cell transplantation (Allo-HSCT): a systematic review, meta-analysis, and meta-regression analysis. Am J Transplant 19(9):2479–2494PubMedCrossRef Gimenez E et al (2019) Cytomegalovirus (CMV) infection and risk of mortality in allogeneic hematopoietic stem cell transplantation (Allo-HSCT): a systematic review, meta-analysis, and meta-regression analysis. Am J Transplant 19(9):2479–2494PubMedCrossRef
14.
go back to reference Chuleerarux N et al (2022) The association of cytomegalovirus infection and cytomegalovirus serostatus with invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients: a systematic review and meta-analysis. Clin Microbiol Infect 28(3):332–344PubMedCrossRef Chuleerarux N et al (2022) The association of cytomegalovirus infection and cytomegalovirus serostatus with invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients: a systematic review and meta-analysis. Clin Microbiol Infect 28(3):332–344PubMedCrossRef
15.
go back to reference Beswick J et al (2018) Incidence and risk factors for nontuberculous mycobacterial infection after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 24(2):366–372PubMedCrossRef Beswick J et al (2018) Incidence and risk factors for nontuberculous mycobacterial infection after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 24(2):366–372PubMedCrossRef
16.
go back to reference Chen J et al (2022) Primary graft failure following allogeneic hematopoietic stem cell transplantation: risk factors, treatment and outcomes. Hematology 27(1):293–299PubMedCrossRef Chen J et al (2022) Primary graft failure following allogeneic hematopoietic stem cell transplantation: risk factors, treatment and outcomes. Hematology 27(1):293–299PubMedCrossRef
17.
go back to reference De Miguel C et al (2018) Clinical impact and burden of CMV infection on the use of resources in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 24(3):S388CrossRef De Miguel C et al (2018) Clinical impact and burden of CMV infection on the use of resources in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 24(3):S388CrossRef
18.
go back to reference Deconinck E et al (2005) Cytomegalovirus infection and chronic graft-versus-host disease are significant predictors of renal failure after allogeneic hematopoietic stem cell transplantation. Haematologica 90(4):569–570PubMed Deconinck E et al (2005) Cytomegalovirus infection and chronic graft-versus-host disease are significant predictors of renal failure after allogeneic hematopoietic stem cell transplantation. Haematologica 90(4):569–570PubMed
19.
go back to reference Hama A et al (2020) Risk factors for secondary poor graft function after bone marrow transplantation in children with acquired aplastic anemia. Pediatr Transplant 24(7):e13828PubMedCrossRef Hama A et al (2020) Risk factors for secondary poor graft function after bone marrow transplantation in children with acquired aplastic anemia. Pediatr Transplant 24(7):e13828PubMedCrossRef
20.
go back to reference Lavallée C et al (2017) Risk factors for the development of Clostridium difficile infection in adult allogeneic hematopoietic stem cell transplant recipients: a single-center study in Québec, Canada. Transplant Infect Dis Off J Transplant Soc 19(1) Lavallée C et al (2017) Risk factors for the development of Clostridium difficile infection in adult allogeneic hematopoietic stem cell transplant recipients: a single-center study in Québec, Canada. Transplant Infect Dis Off J Transplant Soc 19(1)
21.
go back to reference Lin F et al (2022) The incidence, outcomes, and risk factors of secondary poor graft function in haploidentical hematopoietic stem cell transplantation for acquired aplastic anemia. Front Immunol 13 Lin F et al (2022) The incidence, outcomes, and risk factors of secondary poor graft function in haploidentical hematopoietic stem cell transplantation for acquired aplastic anemia. Front Immunol 13
22.
go back to reference Lv WR et al (2021) Haploidentical donor transplant is associated with secondary poor graft function after allogeneic stem cell transplantation: a single-center retrospective study. Cancer Med 10(23):8497–8506PubMedPubMedCentralCrossRef Lv WR et al (2021) Haploidentical donor transplant is associated with secondary poor graft function after allogeneic stem cell transplantation: a single-center retrospective study. Cancer Med 10(23):8497–8506PubMedPubMedCentralCrossRef
23.
go back to reference Madsen K et al (2020) Incidence, outcomes and predictors of acute kidney injury post allogeneic stem cell transplant. Blood. 136((Madsen K.; Chen S.; Pasic I.) Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada): p. 16–17. Madsen K et al (2020) Incidence, outcomes and predictors of acute kidney injury post allogeneic stem cell transplant. Blood. 136((Madsen K.; Chen S.; Pasic I.) Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada): p. 16–17.
24.
go back to reference Masouridi Levrat S et al (2016) Impact of different methods of T-cell depletion on poor graft function incidence after allogeneic hematopoietic stem cell transplantation. Bone marrow transplantation. 51((Masouridi Levrat S.; Simonetta F.; Tirefort Y.; Tsopra O.; Dantin C.; Beauverd Y.; Simon A.; Polchlopeck K.; Stephan C.; Chalandon Y.) Hematology, Geneva University Hospitals, Geneva, Switzerland): p. S429-S430. Masouridi Levrat S et al (2016) Impact of different methods of T-cell depletion on poor graft function incidence after allogeneic hematopoietic stem cell transplantation. Bone marrow transplantation. 51((Masouridi Levrat S.; Simonetta F.; Tirefort Y.; Tsopra O.; Dantin C.; Beauverd Y.; Simon A.; Polchlopeck K.; Stephan C.; Chalandon Y.) Hematology, Geneva University Hospitals, Geneva, Switzerland): p. S429-S430.
25.
go back to reference Prabahran A et al (2021) Evaluation of risk factors for and subsequent mortality from poor graft function (PGF) post allogeneic stem cell transplantation. Leuk Lymphoma 62(6):1482–1489PubMedCrossRef Prabahran A et al (2021) Evaluation of risk factors for and subsequent mortality from poor graft function (PGF) post allogeneic stem cell transplantation. Leuk Lymphoma 62(6):1482–1489PubMedCrossRef
26.
go back to reference Prabahran AA et al (2021) Recurrent CMV viremia portends poor prognosis and results in significant resource utilization in patients with poor graft function post allogeneic stem cell transplantation. Blood 138((Prabahran A.A.; Chee L.C.Y.; Koldej R.M.; Ritchie D.) ACRF Translational Research Laboratory, The Royal Melbourne Hospital, Parkville, Australia): p. 4854. Prabahran AA et al (2021) Recurrent CMV viremia portends poor prognosis and results in significant resource utilization in patients with poor graft function post allogeneic stem cell transplantation. Blood 138((Prabahran A.A.; Chee L.C.Y.; Koldej R.M.; Ritchie D.) ACRF Translational Research Laboratory, The Royal Melbourne Hospital, Parkville, Australia): p. 4854.
27.
go back to reference Sano H et al (2017) African American race is a newly identified risk factor for postengraftment blood stream infections in pediatric allogeneic blood and marrow transplantation. Biol Blood Marrow Transplant 23(2):357–360PubMedCrossRefADS Sano H et al (2017) African American race is a newly identified risk factor for postengraftment blood stream infections in pediatric allogeneic blood and marrow transplantation. Biol Blood Marrow Transplant 23(2):357–360PubMedCrossRefADS
28.
go back to reference Saullo JL et al (2020) Cytomegalovirus in allogeneic hematopoietic transplantation: impact on costs and clinical outcomes using a preemptive strategy. Biol Blood Marrow Transplant 26(3):568–580PubMedCrossRef Saullo JL et al (2020) Cytomegalovirus in allogeneic hematopoietic transplantation: impact on costs and clinical outcomes using a preemptive strategy. Biol Blood Marrow Transplant 26(3):568–580PubMedCrossRef
29.
go back to reference Schelfhout J et al (2020) Impact of cytomegalovirus complications on resource utilization and costs following hematopoietic stem cell transplant. Curr Med Res Opin 36(1):33–41PubMedCrossRef Schelfhout J et al (2020) Impact of cytomegalovirus complications on resource utilization and costs following hematopoietic stem cell transplant. Curr Med Res Opin 36(1):33–41PubMedCrossRef
30.
go back to reference Skert C et al (2014) A specific Toll-like receptor profile on T lymphocytes and values of monocytes correlate with bacterial, fungal, and cytomegalovirus infections in the early period of allogeneic stem cell transplantation. Transpl Infect Dis 16(5):697–712PubMedCrossRef Skert C et al (2014) A specific Toll-like receptor profile on T lymphocytes and values of monocytes correlate with bacterial, fungal, and cytomegalovirus infections in the early period of allogeneic stem cell transplantation. Transpl Infect Dis 16(5):697–712PubMedCrossRef
31.
go back to reference Sun Y, Huang XJ (2019) Virus reactivation and low dose of CD34+ cell were associatied with secondary poor graft function within the first 100 days after allogeneic stem cell transplantation. Bone marrow transplantation, 54((Sun Y.; Huang X.-J.) Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China): p. 265–266. Sun Y, Huang XJ (2019) Virus reactivation and low dose of CD34+ cell were associatied with secondary poor graft function within the first 100 days after allogeneic stem cell transplantation. Bone marrow transplantation, 54((Sun Y.; Huang X.-J.) Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China): p. 265–266.
32.
go back to reference Sun YQ et al (2019) Virus reactivation and low dose of CD34+ cell, rather than haploidentical transplantation, were associated with secondary poor graft function within the first 100 days after allogeneic stem cell transplantation. Ann Hematol 98(8):1877–1883PubMedCrossRef Sun YQ et al (2019) Virus reactivation and low dose of CD34+ cell, rather than haploidentical transplantation, were associated with secondary poor graft function within the first 100 days after allogeneic stem cell transplantation. Ann Hematol 98(8):1877–1883PubMedCrossRef
33.
go back to reference Teschner D et al (2022) Cytomegalovirus infection and rehospitalization rates after allogeneic hematopoietic stem cell and solid organ transplantation: a retrospective cohort study using German claims data. Infection 50(6):1543–1555PubMedPubMedCentralCrossRef Teschner D et al (2022) Cytomegalovirus infection and rehospitalization rates after allogeneic hematopoietic stem cell and solid organ transplantation: a retrospective cohort study using German claims data. Infection 50(6):1543–1555PubMedPubMedCentralCrossRef
34.
go back to reference Vinuesa V et al (2016) Lack of evidence for a reciprocal interaction between bacterial and cytomegalovirus infection in the allogeneic stem cell transplantation setting. Transplant Int Off J Eur Soc Organ Transplant 29(11):1196–1204CrossRef Vinuesa V et al (2016) Lack of evidence for a reciprocal interaction between bacterial and cytomegalovirus infection in the allogeneic stem cell transplantation setting. Transplant Int Off J Eur Soc Organ Transplant 29(11):1196–1204CrossRef
35.
go back to reference Xiao Y et al (2014) Risk-factor analysis of poor graft function after allogeneic hematopoietic stem cell transplantation. Int J Med Sci 11(6):652–657PubMedPubMedCentralCrossRef Xiao Y et al (2014) Risk-factor analysis of poor graft function after allogeneic hematopoietic stem cell transplantation. Int J Med Sci 11(6):652–657PubMedPubMedCentralCrossRef
36.
go back to reference Yamagishi Y et al (2019) Risk factors and survival impact of readmission after single-unit cord blood transplantation for adults. Int J Hematol 109(1):115–124PubMedCrossRef Yamagishi Y et al (2019) Risk factors and survival impact of readmission after single-unit cord blood transplantation for adults. Int J Hematol 109(1):115–124PubMedCrossRef
37.
go back to reference Sousa H et al (2014) Cytomegalovirus infection in patients who underwent allogeneic hematopoietic stem cell transplantation in Portugal: a five-year retrospective review. Biol Blood Marrow Transplant 20(12):1958–1967PubMedCrossRefADS Sousa H et al (2014) Cytomegalovirus infection in patients who underwent allogeneic hematopoietic stem cell transplantation in Portugal: a five-year retrospective review. Biol Blood Marrow Transplant 20(12):1958–1967PubMedCrossRefADS
38.
go back to reference Takenaka K et al (2015) Cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation is associated with a reduced risk of relapse in patients with acute myeloid leukemia who survived to day 100 after transplantation: the Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group. Biol Blood Marrow Transplant 21(11):2008–2016PubMedCrossRef Takenaka K et al (2015) Cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation is associated with a reduced risk of relapse in patients with acute myeloid leukemia who survived to day 100 after transplantation: the Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group. Biol Blood Marrow Transplant 21(11):2008–2016PubMedCrossRef
39.
go back to reference Haidar G, Boeckh M, Singh N (2020) Cytomegalovirus infection in solid organ and hematopoietic cell transplantation: state of the evidence. J Infect Dis 221(Suppl 1):S23-s31PubMedPubMedCentralCrossRef Haidar G, Boeckh M, Singh N (2020) Cytomegalovirus infection in solid organ and hematopoietic cell transplantation: state of the evidence. J Infect Dis 221(Suppl 1):S23-s31PubMedPubMedCentralCrossRef
40.
go back to reference Eberhardt KA et al (2023) CMV-IgG pre-allogeneic hematopoietic stem cell transplantation and the risk for CMV reactivation and mortality. Bone Marrow Transplant Eberhardt KA et al (2023) CMV-IgG pre-allogeneic hematopoietic stem cell transplantation and the risk for CMV reactivation and mortality. Bone Marrow Transplant
41.
go back to reference Elmaagacli AH, Koldehoff M (2016) Cytomegalovirus replication reduces the relapse incidence in patients with acute myeloid leukemia. Blood 128(3):456–459PubMedCrossRef Elmaagacli AH, Koldehoff M (2016) Cytomegalovirus replication reduces the relapse incidence in patients with acute myeloid leukemia. Blood 128(3):456–459PubMedCrossRef
42.
go back to reference Green ML et al (2013) CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood 122(7):1316–1324PubMedPubMedCentralCrossRef Green ML et al (2013) CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood 122(7):1316–1324PubMedPubMedCentralCrossRef
43.
go back to reference Maschmeyer G et al (2022) Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN). Leukemia 36(5):1215–1226PubMedPubMedCentralCrossRef Maschmeyer G et al (2022) Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN). Leukemia 36(5):1215–1226PubMedPubMedCentralCrossRef
44.
go back to reference Yong MK et al (2021) American Society for Transplantation and Cellular Therapy Series: #4 - Cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation. Transplant Cell Ther 27(12):957–967PubMedCrossRef Yong MK et al (2021) American Society for Transplantation and Cellular Therapy Series: #4 - Cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation. Transplant Cell Ther 27(12):957–967PubMedCrossRef
45.
go back to reference Luo XH et al (2018) The impact of inflationary cytomegalovirus-specific memory T cells on anti-tumour immune responses in patients with cancer. Immunology 155(3):294–308PubMedPubMedCentralCrossRef Luo XH et al (2018) The impact of inflationary cytomegalovirus-specific memory T cells on anti-tumour immune responses in patients with cancer. Immunology 155(3):294–308PubMedPubMedCentralCrossRef
46.
go back to reference Luo XH et al (2022) Different recovery patterns of CMV-specific and WT1-specific T cells in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: Impact of CMV infection and leukemia relapse. Front Immunol 13:1027593PubMedCrossRef Luo XH et al (2022) Different recovery patterns of CMV-specific and WT1-specific T cells in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: Impact of CMV infection and leukemia relapse. Front Immunol 13:1027593PubMedCrossRef
47.
go back to reference Fan ZY et al (2022) CMV infection combined with acute GVHD associated with poor CD8+ T-cell immune reconstitution and poor prognosis post-HLA-matched allo-HSCT. Clin Exp Immunol 208(3):332–339MathSciNetPubMedPubMedCentralCrossRef Fan ZY et al (2022) CMV infection combined with acute GVHD associated with poor CD8+ T-cell immune reconstitution and poor prognosis post-HLA-matched allo-HSCT. Clin Exp Immunol 208(3):332–339MathSciNetPubMedPubMedCentralCrossRef
48.
go back to reference Cantoni N et al (2010) Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease. Biol Blood Marrow Transplant 16(9):1309–1314PubMedCrossRef Cantoni N et al (2010) Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease. Biol Blood Marrow Transplant 16(9):1309–1314PubMedCrossRef
49.
go back to reference Shi JM et al (2015) Invasive fungal infection in allogeneic hematopoietic stem cell transplant recipients: single center experiences of 12 years. J Zhejiang Univ Sci B 16(9):796–804PubMedPubMedCentralCrossRef Shi JM et al (2015) Invasive fungal infection in allogeneic hematopoietic stem cell transplant recipients: single center experiences of 12 years. J Zhejiang Univ Sci B 16(9):796–804PubMedPubMedCentralCrossRef
50.
go back to reference Atalla A et al (2015) Risk factors for invasive mold diseases in allogeneic hematopoietic cell transplant recipients. Transpl Infect Dis 17(1):7–13PubMedCrossRef Atalla A et al (2015) Risk factors for invasive mold diseases in allogeneic hematopoietic cell transplant recipients. Transpl Infect Dis 17(1):7–13PubMedCrossRef
51.
go back to reference Yong MK et al (2017) Cytomegalovirus reactivation is associated with increased risk of late-onset invasive fungal disease after allogeneic hematopoietic stem cell transplantation: a multicenter study in the current era of viral load monitoring. Biol Blood Marrow Transplant 23(11):1961–1967PubMedCrossRef Yong MK et al (2017) Cytomegalovirus reactivation is associated with increased risk of late-onset invasive fungal disease after allogeneic hematopoietic stem cell transplantation: a multicenter study in the current era of viral load monitoring. Biol Blood Marrow Transplant 23(11):1961–1967PubMedCrossRef
52.
go back to reference Pierce B et al (2018) Safety and efficacy of foscarnet for the management of ganciclovir-resistant or refractory cytomegalovirus infections: a single-center study. Transpl Infect Dis 20(2):e12852PubMedCrossRef Pierce B et al (2018) Safety and efficacy of foscarnet for the management of ganciclovir-resistant or refractory cytomegalovirus infections: a single-center study. Transpl Infect Dis 20(2):e12852PubMedCrossRef
53.
go back to reference Halouzková BA et al (2022) Dosing of aminoglycosides in chronic kidney disease and end-stage renal disease patients treated with intermittent hemodialysis. Kidney Blood Press Res 47(7):448–458PubMedCrossRef Halouzková BA et al (2022) Dosing of aminoglycosides in chronic kidney disease and end-stage renal disease patients treated with intermittent hemodialysis. Kidney Blood Press Res 47(7):448–458PubMedCrossRef
54.
go back to reference Zaucha-Prazmo A et al (2005) Cytomegalovirus (CMV) infections in children undergoing hematopoetic stem cell transplantation. Pediatr Hematol Oncol 22(4):271–276PubMedCrossRef Zaucha-Prazmo A et al (2005) Cytomegalovirus (CMV) infections in children undergoing hematopoetic stem cell transplantation. Pediatr Hematol Oncol 22(4):271–276PubMedCrossRef
55.
go back to reference Kong Y (2019) Poor graft function after allogeneic hematopoietic stem cell transplantation-an old complication with new insights(☆). Semin Hematol 56(3):215–220PubMedCrossRef Kong Y (2019) Poor graft function after allogeneic hematopoietic stem cell transplantation-an old complication with new insights(☆). Semin Hematol 56(3):215–220PubMedCrossRef
56.
go back to reference Girmenia C et al (2017) Incidence, risk factors and outcome of pre-engraftment gram-negative bacteremia after allogeneic and autologous hematopoietic stem cell transplantation: an Italian prospective multicenter survey. Clin Infect Dis 65(11):1884–1896PubMedCrossRef Girmenia C et al (2017) Incidence, risk factors and outcome of pre-engraftment gram-negative bacteremia after allogeneic and autologous hematopoietic stem cell transplantation: an Italian prospective multicenter survey. Clin Infect Dis 65(11):1884–1896PubMedCrossRef
57.
go back to reference Öksüz L et al (2022) The association of CMV infection with bacterial and fungal infections in hematopoietic stem cell transplant recipients: a retrospective single-center study. New Microbiol 45(1):40–50PubMed Öksüz L et al (2022) The association of CMV infection with bacterial and fungal infections in hematopoietic stem cell transplant recipients: a retrospective single-center study. New Microbiol 45(1):40–50PubMed
58.
go back to reference Wang CH et al (2018) Characteristics comparisons of bacteremia in allogeneic and autologous hematopoietic stem cell-transplant recipients with levofloxacin prophylaxis and influence on resistant bacteria emergence. J Microbiol Immunol Infect 51(1):123–131PubMedCrossRef Wang CH et al (2018) Characteristics comparisons of bacteremia in allogeneic and autologous hematopoietic stem cell-transplant recipients with levofloxacin prophylaxis and influence on resistant bacteria emergence. J Microbiol Immunol Infect 51(1):123–131PubMedCrossRef
59.
go back to reference Khawaja F et al (2023) Cytomegalovirus infection in transplant recipients: newly approved additions to our armamentarium. Clin Microbiol Infect 29(1):44–50PubMedCrossRef Khawaja F et al (2023) Cytomegalovirus infection in transplant recipients: newly approved additions to our armamentarium. Clin Microbiol Infect 29(1):44–50PubMedCrossRef
60.
go back to reference Marty FM et al (2017) Letermovir Prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med 377(25):2433–2444PubMedCrossRef Marty FM et al (2017) Letermovir Prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med 377(25):2433–2444PubMedCrossRef
61.
go back to reference Marty FM et al (2020) Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation. Am J Transplant 20(6):1703–1711PubMedCrossRef Marty FM et al (2020) Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation. Am J Transplant 20(6):1703–1711PubMedCrossRef
Metadata
Title
The indirect effects of CMV reactivation on patients following allogeneic hematopoietic stem cell transplantation: an evidence mapping
Authors
Xiaojin Wu
Xiao Ma
Tiemei Song
Jie Liu
Yi Sun
Depei Wu
Publication date
16-01-2024
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 3/2024
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-023-05509-7

Other articles of this Issue 3/2024

Annals of Hematology 3/2024 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare